# Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

> **NCT05316467** · PHASE2,PHASE3 · RECRUITING · sponsor: **Xiaojun Chen** · enrollment: 89 (estimated)

## Conditions studied

- Endometrial Carcinoma
- Obese
- Overweight
- Fertility Issues

## Interventions

- **BEHAVIORAL:** Intensive Lifestyle Intervention (ILI)
- **DRUG:** Megestrol Acetate 160 MG Oral Tablet

## Key facts

- **NCT ID:** NCT05316467
- **Lead sponsor:** Xiaojun Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-01
- **Primary completion:** 2026-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 89 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05316467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05316467, "Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05316467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*